Aug 6, 2026 · 6 min
Moderna rises on vaccine approval while Honeywell plunges on supply issues
Moderna Drops, DoorDash Rises, Honeywell Plunges as Surprise Guidance Cut Alarms Wall Street
Understanding these divergent stock movements highlights how regulatory milestones and supply chain health are actively reshaping market leadership.
- 1Moderna secured US regulatory approval for its new mRNA-based flu vaccine designed for older adults.
- 2Honeywell suffered a sharp stock decline after cutting its full-year outlook due to persistent supply chain issues.
- 3DoorDash raised its profit forecast following a substantial surge in paying subscribers.
Don't miss
Kristine Aquino breaks down how Honeywell's reduced full-year outlook shocked Wall Street.
The brief
The latest market movements reveal a stark contrast in corporate fortunes, as regulatory victories propel biotech stocks forward while persistent supply chain bottlenecks drag down industrial giants.
Moderna secured a critical win with US regulatory approval for its mRNA-based flu vaccine, mFlusiva, targeting older adults and marking a major milestone for its next-generation immunization technology.
In contrast, industrial conglomerate Honeywell faced a sharp stock plunge after a surprise guidance cut, signaling that supply chain disruptions continue to hamper major manufacturing operations.
Meanwhile, DoorDash defied broader market anxieties, raising its profit forecast on the back of a significant surge in paying subscribers who are driving consistent platform growth.
What was said on this episode
7 statements · 3 positive · 3 negative · 1 neutral
Moderna received US approval for an mRNA-based flu vaccine.
“the company won US regulatory approval for a flu vaccine based on MRNA technology”
Listen at 1:13
The approval enables FDA consideration of Moderna’s combined flu-COVID vaccine.
“it does set the scene for the FDA to consider next steps for the more important flu plus COVID vaccine”
Listen at 1:43
DoorDash reported strong second-quarter results, with revenue and adjusted EBITDA above estimates.
“a pretty solid set of results. Second quarter revenue and adjusted EBITDA beating estimates”
Listen at 2:21
DoorDash’s free cash flow and EPS fell short of expectations.
“free cash flow and EPS missing expectations”
Listen at 2:27
DoorDash is directing substantial technology spending toward delivery robots and drones.
“a lot of that is going into its in house robotics efforts to build delivery robots and drones”
Listen at 2:38
The speaker is lukewarm about robot delivery.
“I think we're a little lukewarm on the idea of delivery of robots and”
Listen at 2:44
Honeywell shares fell more than 20%, making it one of the S&P 500’s biggest decliners.
“that stock is very much in the red this morning. One of the biggest decliners on the S&P 500 ticker H O N A shares are down now more than 20%”
Listen at 2:54
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
mRNA-based flu vaccineBooks & mentions
Listen to the full episode and explore every guest, topic, and moment on PodLume.